What topics does this cannabis study cover?

This study covers research on: Pain, Cancer, THC.

Where was this research published?

Published in The oncologist on April 28, 2026.

Dronabinol helps cancer patients reduce opioid use for bone pain

Q: What did this research study find?

This pilot study evaluated *dronabinol* (a synthetic form of THC) as an addition to opioid therapy for **cancer-induced bone pain** from breast cancer metastases. Fourteen patients with advanced breast cancer received **10 mg dronabinol twice daily for 8 weeks** while continuing their regular opioid

Evaluation of Dronabinol to Decrease Opioid Use for Cancer-Induced Bone Pain.

The oncologist • April 28, 2026 • Moderately Relevant

🤖

AI Summary

This pilot study evaluated dronabinol (a synthetic form of THC) as an addition to opioid therapy for cancer-induced bone pain from breast cancer metastases. Fourteen patients with advanced breast cancer received 10 mg dronabinol twice daily for 8 weeks while continuing their regular opioid treatment. The results showed that 4 out of 14 patients (29%) successfully reduced their opioid use by at least 20%, meeting the study's primary goal. Beyond opioid reduction, patients reported significant improvements in pain severity, pain interference with daily activities, overall quality of life, and sleep problems, demonstrating benefits beyond just medication reduction.

The study also found encouraging biological markers of improvement: there was a significant decrease in serum C-terminal telopeptide levels, a key indicator of bone breakdown that's elevated in cancer-related bone disease. Safety was generally favorable, with only one grade 3 adverse event (dizziness) directly related to the medication among all participants. This suggests that dronabinol was well-tolerated in this patient population. The findings are particularly significant because they represent one of the first clinical attempts to use cannabinoids specifically to address the dual problem of cancer pain and opioid dependence.

These results, while modest in scope, provide encouraging evidence that cannabinoid-based therapies could offer a meaningful alternative for cancer patients struggling with inadequate pain control and opioid side effects. The researchers note that larger, controlled studies are needed to confirm these findings and optimize dosing strategies.

📄 Original Abstract

Bone metastases (BM) from breast cancer cause significant cancer-induced bone pain (CIBP). Management of CIBP is primarily with opioids, which have notable side effects. In preclinical models, cannabinoid receptor (CB)2 and CB1 agonists were shown to decrease CIBP and bone degradation. We hypothesized that the addition of CB2/CB1 agonists would decrease opioid requirements in patients with BM. We conducted a single-arm study among breast cancer patients with BM on opioid therapy. Patients were treated with 10 mg dronabinol BID for 8 weeks. Our primary objective was to determine the proportion who decreased their opioid use by ≥ 20%. Participants completed the Brief Pain Inventory and the European Organization for Research and Treatment of Cancer quality of life questionnaires before and after treatment. Pre- and post-treatment blood and urine were collected for analysis of biomarkers of bone remodeling. We enrolled 14 evaluable patients, and 4 decreased opioid use by ≥ 20%, meeting the primary endpoint. Patients reported significant improvements in pain severity, interference scores, quality of life, and insomnia. There was one grade 3 adverse event (dizziness) related to the study drug. A significant decrease was noted in serum C-terminal telopeptide levels with therapy. Our pilot study shows that the addition of dronabinol resulted in decreased opioid requirements for CIBP. Patient-reported outcomes also demonstrated improved pain and QOL with addition of dronabinol. Our results are promising and warrant further investigation into novel analgesics for CIBP to decrease opioid use.